INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		08619649
Filing Date		1994-09-27
First Named Inventor Rado		e Drmanac
Art Unit		1634
Examiner Name Betty		J. Forman
Attorney Docket Number		02537-23727US03

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5002867		1991-03-26	Macevicz	
	2	5143853		1992-09-01	Pirrung et al.	
	3	5384261		1995-01-24	Winkler et al.	
	4	5424186		1995-06-13	Fodor et al.	
	5	5436327		1995-07-25	Southern et al.	
	6	5492806		1996-02-20	Drmanac et al.	
	7	5525464		1996-06-11	Drmanac et al.	
	8	5578832		1996-11-26	Trulson et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

5695940

	Application Number		08619649
	Filing Date		1994-09-27
	First Named Inventor Rado		je Drmanac
	Art Unit		1634
	Examiner Name Betty		J. Forman
	Attornou Docket Number		02537-2372711503

	,	3033340		1557-12-05	Dillianac et al.	
	10	5744305		1998-04-28	Fodor et al.	
	11	5763176		1998-06-09	Slater et al.	
	12	5800992		1998-09-01	Fodor et al.	
	13	5972619		1999-10-26	Drmanac et al.	
	14	6018041		2000-01-25	Drmanac et al.	
	15	6025136		2000-02-15	Drmanac	
If you wish	h to add	additional U.S. Paten	t citatio	n information pl	ease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					
If you wisl	h to add	additional U.S. Publis			n information please click the Ade	
				FOREIGN PAT	TENT DOCUMENTS	Remove

1997-12-09 Drmanac et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		08619649
Filing Date		1994-09-27
First Named Inventor Radol		e Drmanac
Art Unit		1634
Examiner Name Betty		J. Forman
		00507 007071 1000

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² į	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	TS
	1	97/27325	wo		1997-07-31	RAPIGENE INC.		
	2	97/27327	wo		1997-07-31	RAPIGENE INC.		
	3	97/27331	wo		1997-07-31	RAPIGENE INC.		
	4	99/60170	wo		1999-11-25	HYSEQ, INC.		
If you wish	h to a	dd additional Foreign P	atent Document	citation	information pl	lease click the Add butto	n Add	
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when approp date, pages(s), volume-is		Тs
	1	Advisory Action in 10/06	8,301, dated April	29, 200	4.			
	2	Advisory Action in 10/06	8,301, dated Augu	ust 2, 20	04.			
	3	Bains et al., J. Theor. Bi	ol., 135.303-307 (1988)				
	4	Cantor et al., "Report or	the sequencing b	y hybrid	zation workshop	p," Genomics, 13(4):1378-1	383 (1992)	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		08619649
Filing Date		1994-09-27
First Named Inventor Rado		e Drmanac
Art Unit		1634
Examiner Name Betty		J. Forman
Attorney Docket Number		02537-23727US03

5	Certificate of Correction in 09/272,232, filed October 30, 2002.	
6	Certificate of Correction in 09/272,232, filed September 17, 2002.	
7	Certificate of Correction in 10068,301, filed January 29, 2007.	
8	Chu et al., Nucleic Acids Research, 11(18):6513-6529 (1983)	
9	Church et al., Proc. Natl. Acad. Sci. USA, 81.1991-1995 (1984)	
10	Church et al., Science, 240:185-188 (1988)	
11	Dahlen et al., Mol. Ceil. Probes, 1.159-168 (1987)	
12	Dmanac et al., Int. J. Gen. Res., 1(1) 59-79 (1992)	
13	Dimanac et al., The Second International Conference on Bioinformatics, Supercomputing and Complex Genome Analysis, June 47, 1992, St. Petersberg Beach, Florida, H.A. Lim, J.W. Flokett, C.R. Cantor, and R.J. Robbins, Eds., World Scientific, Publishers, pp. 121-134 (1993)	
14	Ekins et al., Trends Biotechnol., 17.217-218 (1999)	
15	Examiner Interview in 10/068,301, dated 04-15-2004.	

16	Fodor et al., Clin. Chem., 40(4),767-773 (1991)	
17	Guenoche et al., Agronomie, 14 363-375 (1994)	
18	Inouye et al., J. Clin, Microb., 28(6):1489-1472 (1990)	
19	Ivanov et al., Nuc. Acids Symp. Ser., 24 189-190 (1991)	
20	Jacobson et al., Cenomics, 8.001-007 (1990)	
21	Khorlin et al., Nuc. Acids. Symp. Ser., 24 191-192 (1991)	
22	Khrapko et al., Nuc. Acids Res., 22(3):984-969 (1994)	
23	Lipshutz et al., Biotechniques, 19(3):442-447 (1995)	
24	Lipshutz et al., Genomics, 19:417-424 (1994)	
25	Lipshutz, Clin. Chem., 40(8):1173 (1994)	
26	Lipshutz, J. Blomol. Struct. Dyn., 11(3):637-653 (1993)	

27	Livshits et al., J. Biomol. Struct. Dyn., 11(4),783-795 (1994)	
28	Maxam et al., Proc. Natl. Acad. Sci. USA, 74(2):560-564 (1977)	
29	Mirzabekov, Trend Biolechnol., 12.27-32 (1994)	
30	Morrissey et al., Mol. Cell. Probes, 3:189-207 (1989)	
31	Nagata et al., FEBS Lett., 183(2) 379-382 (1985)	
32	Notice of Allowance in 09/272,232, dated December 18, 2001.	
33	Notice of Allowance in 10/068,301, dated February 2, 2005.	
34	Office Action in 08/127,420, dated April 4, 1994	
35	Office Action in 09/272,232, dated August 15, 2001.	
36	Office Action in 09/272,232, dated May 12, 2000.	
37	Office Action in 10/068,301, dated April 9, 2003.	

38	Office Action in 10/068,301, dated December 29, 2003.	
39	Office Action in 10/058,301, dated July 2, 2003.	
40	Petition Decision in 10/058,301, dated December 30, 2004.	
41	Petition to Revive in 10/088,301, filed September 10, 2004.	
42	Postinov et al., Nuc. Acids Res., 19(4):717-725 (1991)	
43	Preliminary Amendment in 09/272,232, filed March 18, 1999	
44	Preliminary Amendment in 10/068,301, filed February 5, 2002.	
45	Request for Continued Examination in 10/088,301, filed September 2, 2004.	
46	Response in 10068,301, filed April 12, 2004	
47	Response in 10/068,301, filed June 1, 2004.	
48	Response in 10/068,301, filed October 1, 2003.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		08619649	
	Filing Date		1994-09-27	
	First Named Inventor	Rado	Radoje Drmanac	
	Art Unit		1634	
	Examiner Name	Betty J. Forman		
	Attorney Docket Number		02537-2372711503	

If you wish to add add	utton Add			
EXAMINER SIGNATURE				
Examiner Signature		Date Considered		
NEVANINED, Initial X of course assistant whether a set distincts in a seferman with MDED 600. Down line to				

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at more_USPTO_GQV or MPEP 901.04. 2 Enter office that issued the document, by the two letter code (WIPO Standard ST.3). 3 Fez, Japanese patent documents, the indication of the year of the rispy of the Emperor must precede the serial number of the patent document. 4 Wind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.61 dis possible. 3 Publicant is no local code chief, many control or specific possible. 3 Publicant is not local code chief, many control or specific possible. 3 Publicant is not possible 3 Publicant is not possible. 3 Publicant is not possible.

English language translation is attached

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		08619649	
Filing Date			1994-09-27	
	First Named Inventor	Rado	e Drmanac	
	Art Unit		1634	
	Examiner Name	Betty J. Forman		
Attorney Docket Number		er	02537-23727US03	

CERTIFICATION STATEMENT

Please see 37	7 CFR 1.9	7 and 1.98 t	o make the	appropriate	selection	s)	
---------------	-----------	--------------	------------	-------------	-----------	----	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

Nahoola P McMillian

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.					
Signature	/Nabeela R. McMillian, #43,363/	Date (YYYY-MM-DD)	2012-05-25		

Registration Number

43363

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Plantant and Trademark Office, U.S. Operatment of Commence, P. 0. Box 1450, Alexandri, V.S. 2213-1440. D. DNOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2213-1450.

Name/Print

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicide to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORice is to process andior examine your submission related to a patient application or patient. If you do not furnish the requested privacy is the principal purpose of which the information is used to patient. If you do not furnish the requested more private in the privacy of the privacy is a privacy of the privacy in the privacy of th

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subiect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA is part of that apency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abavit individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 159 or issuance of a patient pursuant to 55 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public fifthe record was filled in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by either a published application, one of public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.